RxDoctor Payments Data

Cynthia Sullivan, APRN

Nurse Practitioner · Indian Harbour Beach, FLNPI 1093034282

Payments from drug & device makers

$639in general payments, 2019–2025

Across 33 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$170
  • Pfizer$97
  • AstraZeneca$96
  • Novo Nordisk$86
  • AbbVie$67
  • Biohaven Pharmaceutical Holding Company Ltd.$44
  • plus $78 from 4 others

What the payments were for

  • Food & beverage$639100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$639 in reported general payments places this provider in the 65th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$97,385
Medicare patients
303
Services billed
10,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban48$64,455
OzempicSemaglutide51$60,511
XareltoRivaroxaban48$50,968
JardianceEmpagliflozin37$47,498
RybelsusSemaglutide21$27,764
Breo ElliptaFluticasone/Vilanterol29$15,789
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,559
WegovySemaglutide11$13,827
Atorvastatin Calcium381$6,055
Levothyroxine Sodium277$4,120
Metoprolol Succinate177$3,491
Ezetimibe98$3,189
Rosuvastatin Calcium175$3,153
Albuterol Sulfate HfaAlbuterol Sulfate100$2,863
Losartan Potassium170$2,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$86$102,10383 claims
PfizerEliquis$97$64,45548 claims
Johnson & JohnsonXarelto$15$50,96848 claims
GSKBreo Ellipta, Trelegy Ellipta$17$30,34851 claims
AbbVieSynthroid$67$2,16534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Indian Harbour Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →